Atyr PHARMA (NASDAQ:ATYR) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Atyr PHARMA (NASDAQ:ATYR) posted its earnings results on Tuesday. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01, Yahoo Finance reports.

Atyr PHARMA Stock Performance

NASDAQ:ATYR traded up $0.04 during trading hours on Wednesday, reaching $1.78. 47,910 shares of the company were exchanged, compared to its average volume of 476,594. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.07 and a current ratio of 6.07. The stock has a market capitalization of $122.68 million, a PE ratio of -1.98 and a beta of 1.25. Atyr PHARMA has a twelve month low of $1.08 and a twelve month high of $2.50.

Insider Buying and Selling at Atyr PHARMA

In other news, Director Paul Schimmel acquired 52,300 shares of the stock in a transaction that occurred on Wednesday, July 24th. The shares were bought at an average cost of $1.93 per share, for a total transaction of $100,939.00. Following the acquisition, the director now owns 413,023 shares in the company, valued at approximately $797,134.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 3.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a report on Thursday, August 1st.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company’s lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.